ASAQ Winthrop®

Sanofi

Product category
  • 3-day cure, artemisinin-based combination therapy (artesunate-amodiaquine)

Therapeutic indication
  • Treatment of uncomplicated P. falciparum malaria in adults, children and infants >5kg

Dosing
  • Once-daily for 3 days

Efficacy
  • 28 day PCR-corrected ACPR* 94.4%–98.9%

Key features
  • Lower price compared to other prequalified ACTs (public-sector tenders)
  • Three-year shelf life
Challenges
  • Amodiaquine resistance in some countries

  • Being withdrawn from countries where SPAQ is deployed for seasonal malaria chemoprevention (SMC) following WHO recommendation

Status
  • 537 million treatments distributed since 2007

  • Approved in 33 countries

Previously
  • DNDi and partners completed development and registration
  • Incorporated into MMV portfolio via collaboration supporting phase IV safety study in Côte d’Ivoire in 2010
MMV Project Director
  • Anthony Okoth

* ACPR = adequate clinical and parasitological response